Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06425549 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Study acronym: BE TOGETHER
StatusActive, Not Recruiting
PhasePhase 3
Started2024-06-25
View on ClinicalTrials.gov ↗

Amendment history

2026-08-18
Study Status, Study Design v22
Enrollment target175→176
2026-08-13
Study Status v21
Re-verified, no change to tracked fields
2026-08-06
Study Status, Study Design, Contacts/Locations v20
Enrollment closed, study ongoing
Trial sites reduced: 50 → 42 locations
Enrollment targetestimated 168→confirmed 175
2026-07-16
Study Status, Contacts/Locations v19
Study sitesdetails revised at 1 of 50 sites
2026-05-21
Study Status, Contacts/Locations v18
Study sitesdetails revised at 1 of 50 sites
Show 17 earlier versions
2026-05-07
Study Status, Contacts/Locations v17
Study sitesdetails revised at 9 of 50 sites
2026-04-09
Study Status, Contacts/Locations v16
Study sitesdetails revised at 1 of 50 sites
2026-03-12
Study Status, Contacts/Locations v15
Study sitesdetails revised at 1 of 50 sites
2026-02-26
Study Status, Contacts/Locations v14
Study sitesdetails revised at 1 of 50 sites
2025-12-24
Study Status, Contacts/Locations v13
Study sitesdetails revised at 38 of 50 sites
2025-11-27
Study Status, Contacts/Locations v12
Study sites49→50
2025-10-01
Study Status, Contacts/Locations v11
Study sites48→49
2025-08-07
Study Status, Contacts/Locations v10
Study sites47→48
2025-07-10
Study Status, Contacts/Locations v9
Study sites46→47
2025-06-26
Study Status, Contacts/Locations v8
Study sitesdetails revised at 1 of 46 sites
2025-06-12
Study Status, Contacts/Locations v7
Study sites45→46
2025-05-29
Study Status, Contacts/Locations v6
Study sitesdetails revised at 1 of 45 sites
2025-05-15
Study Status, Contacts/Locations v5
Study sitesdetails revised at 1 of 45 sites
2025-04-17
Study Status, Contacts/Locations v4
Study sites43→45
2025-04-03
Study Status, Contacts/Locations v3
Study sites7→43
2024-07-25
Study Status, Contacts/Locations v2
Start dateestimated 2024-06-07→confirmed 2024-06-25
Study sites3→7
2024-06-05
Not Yet Recruiting→Recruiting Study Status, Conditions, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start date2024-05→2024-06-07
Study sites0→3
2024-05-17
Original filing
UCB Biopharma SRL
68 trials monitored
See 4 trials at risk
Psoriasis
418 trials monitored
See 17 trials at risk
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).
Trial Details
NCT Number NCT06425549
Lead Sponsor UCB Biopharma SRL
Conditions Moderate to Severe Plaque Psoriasis
Enrollment 176 participants
Start Date 2024-06-25
Primary Completion 2028-08-21 (estimated)
Study Completion 2030-11-08 (estimated)
Updated on ClinicalTrials.gov 2026-09-18